2013 Historical

Financial

Review

he Historical Financial Review is prepared once per year and is

available on line at www.investor.jnj.com. It is intended to supplement the Annual Report and other SEC filings and be used primarily by financial analysts to assist in a detailed financial analysis. While this document does include abbreviated financial statements, it is not a substitute

for the more detailed financial statements (including footnotes) found in the Annual Report and other SEC filings. We appreciate your comments and suggestions on ways to improve this document and will attempt to incorporate them into future editions.

Index Page

T

Introduction 1 Five –Year Selected Financial Data 2 Description of Major Business Franchises 3 Balance Sheets, Statements of Earnings, Statements of Cash Flows 4-6 Segments of Business Information 7-8 Geographical Areas 9 Sales Growth Rates 10 Quarterly Sales and Earnings Information 11-14 Sales and Net Earnings 1887-2013 15 Stock Split and Share Repurchase Information 16 Common Stock Information 1944-2013 17-18 Reconciliation of Non-GAAP Measures 19 Corporate and Shareholder/Investor Information 20

Historical Financial Review

1

Johnson & Johnson and Subsidiaries:Five-Year Selected Financial Data 2009-2013

(Dollars in Millions Except Per Share Figures)

Operating Results 2013 (1) 2012 (1) 2011 (1) 2010 (1) 2009 (1)

Sales to customers 71,312$ 67,224 65,030 61,587 61,897 Earnings before provision for taxes on income 15,471 13,775 12,361 16,947 15,755 Net earnings attributable to J&J (2) 13,831 10,853 9,672 13,334 12,266 Basic net earnings per share 4.92$ 3.94 3.54 4.85 4.45 Diluted net earnings per share 4.81$ 3.86 3.49 4.78 4.40

StatisticsBefore tax margin 21.7 % 20.5 19.0 27.5 25.4 Net profit margin (2) 19.4 16.1 14.9 21.7 19.8 Effective tax rate 10.6 23.7 21.8 21.3 22.1 Return on average shareholders' equity 19.9 17.8 17.0 24.9 26.4 Return on total assets 10.4 % 8.9 8.5 13.0 13.0

Capital StructureCash and Current Marketable Securities 29,206$ 21,089 32,261 27,658 19,425

Debt 18,180 16,165 19,627 16,773 14,541 Equity 74,053 64,826 57,080 56,579 50,588 Total capital 92,233 80,991 76,707 73,352 65,129 Net cash/(debt) 11,026$ 4,924 12,634 10,885 4,884

Total debt/total capital 19.7 % 20.0 25.6 22.9 22.3

Common Stock InformationDividends paid per share 2.590$ 2.400 2.250 2.110 1.930 Shareholders' equity per share 26.25$ 23.33 20.95 20.66 18.37 Market price per share (year end close) 92.35$ 69.48 65.58 61.85 64.41 Average shares outstanding (mm) - basic 2,809.2 2,753.3 2,736.0 2,751.4 2,759.5 - diluted 2,877.0 2,812.6 2,775.3 2,788.8 2,789.1 Cash dividends 7,286$ 6,614 6,156 5,804 5,327

Other DataTotal assets 132,683$ 121,347 113,644 102,908 94,682 Research & development expense 8,183 7,665 7,548 6,844 6,986 Capital expenditures 3,595$ 2,934 2,893 2,384 2,365 Number of employees (thousands) 128.1 127.6 117.9 114.0 115.5

(1) For Adjusted earnings (before and after tax) and adjusted earnings per share, see Reconciliation of Non-GAAP Measures on Page 19.(2) After noncontrolling interests

2

Consumer Segment

The Consumer segment includes a broad range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products and wellness and prevention platforms. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Baby Care franchise includes the JOHNSON’S® Baby line of products. Major brands in the Skin Care franchise include the AVEENO®; CLEAN & CLEAR®; JOHNSON’S® Adult; NEUTROGENA®; RoC®; LUBRIDERM®; and DABAOTM product lines. The Oral Care franchise includes the LISTERINE® oral care lines. The Wound Care franchise includes BAND-AID® brand adhesive bandages and NEOSPORIN® First Aid products. Major brands in the Women’s Health franchise outside of North America are CAREFREE®

Pantiliners; o.b. ® tampons and STAYFREE® sanitary protection products. The principal nutritional line is SPLENDA® No Calorie Sweetener. Over-the-counter medicines include the broad family of TYLENOL® acetaminophen products; SUDAFED® cold, flu and allergy products; ZYRTEC® allergy products; MOTRIN® IB ibuprofen products; and PEPCID® AC® Acid Controller.

Medical Devices and Diagnostics Segment

The Medical Devices & Diagnostics segment includes a broad range of products distributed to wholesales, hospitals and retailers, used principally in the professional fields by physicians, nurses, hospitals and clinics. These include products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses.

Pharmaceutical Segment

The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hema-tology, immunology, infectious diseases, metabolic, neurology, oncology, pain management and vaccines. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use.

Key products in the Pharmaceutical segment include: REMICADE® (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI®(golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA® (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO® (telaprevir), for the treatment of hepatitis C; INTELENCE® (etravirine) and PREZISTA® (darunavir), treatments for HIV/AIDS; CONCERTA® (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA® (paliperidone) extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA® SUSTENNA® /XEPLION® (paliperidone palmitate), for the treatment of schizophrenia in adults; RISPERDAL® CONSTA® (risperidone), for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE® (bortezomib), a treatment for multiple myeloma; ZYTIGA® (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer; ACIPHEX® /PARIET® , a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT® (epoetin alfa, sold outside the U.S. as EPREX® ), to stimulate red blood cell production; and XARELTO® (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of DVT and PE, and for the reduction in the risk of recurrence of DVT and PE.

Newly launched products in the Pharmaceutical segment include: INVOKANA® (canagliflozin), a treatment for type 2 diabetes; OLYSIOTM (simeprevir), for the treatment of chronic hepatitis C; and IMBRUVICATM (Ibrutinib), for the treatment of mantle cell lymphoma.

Description of Major Business Franchises

3

Johnson & Johnson and Subsidiaries:Consolidated Balance Sheets (Dollars in Millions)

Assets 2013 2012 2011Current assets

Cash and cash equivalents 20,927$ 14,911 24,542 Marketable securities 8,279 6,178 7,719 Accounts receivable trade, less allowance for doubtful accounts 11,713 11,309 10,581 Inventories 7,878 7,495 6,285 Other current assets 7,610 6,223 5,189

Total current assets 56,407 46,116 54,316

Property, plant and equipment, net 16,710 16,097 14,739 Intangible assets, net and Goodwill 50,745 51,176 34,276 Other non-current assets 8,821 7,958 10,313

Total assets 132,683$ 121,347 113,644

Liabilities and Shareholders' EquityCurrent liabilities

Loans and notes payable 4,852$ 4,676 6,658 Accounts payable 6,266 5,831 5,725 Accrued liabilities 13,787 12,691 9,574 Accrued taxes on income 770 1,064 854

Total current liabilities 25,675 24,262 22,811

Long-term debt 13,328 11,489 12,969 Other long-term liabilities 19,627 20,770 20,784 Total liabilities 58,630 56,521 56,564

Shareholders' equityCommon stock 3,120 3,120 3,120 Accumulated other comprehensive income (2,860) (5,810) (5,632) Retained earnings 89,493 85,992 81,251

89,753 83,302 78,739

Less: common stock held in treasury, at cost 15,700 18,476 21,659

Total shareholders' equity 74,053$ 64,826 57,080

Total liabilities and shareholders' equity 132,683$ 121,347 113,644

4

Johnson & Johnson and Subsidiaries:Consolidated Statements of Earnings (Dollars in Millions Except Per Share Figures)

2013 (1) 2012 (1) 2011 (1) 2010 (1) 2009 (1)

Sales to customers 71,312$ 67,224$ 65,030$ 61,587$ 61,897$

Cost of products sold 22,342 21,658 20,360 18,792 18,447 Gross profit 48,970 45,566 44,670 42,795 43,450

Selling, marketing and administrative expenses 21,830 20,869 20,969 19,424 19,801 Research and development expense 8,183 7,665 7,548 6,844 6,986 In-process research and development 580 1,163 - - - Interest income (74) (64) (91) (107) (90) Interest expense, net of portion capitalized 482 532 571 455 451 Other (income) expense, net 2,498 1,626 2,743 (768) (526) Restructuring - - 569 - 1,073

Earnings before provision for taxes on income 15,471 13,775 12,361 16,947 15,755 Provision for taxes on income 1,640 3,261 2,689 3,613 3,489

Net earnings 13,831 10,514 9,672 13,334 12,266 Add: Net loss attributable to noncontrolling interests - 339 - - - Net earnings attributable to Johnson & Johnson 13,831 10,853 9,672 13,334 12,266

Basic net earnings per share attributable to J&J 4.92$ 3.94$ 3.54$ 4.85$ 4.45$ Diluted net earnings per share attributable to J&J 4.81$ 3.86$ 3.49$ 4.78$ 4.40$

Ratios to SalesSales to customers 100.0% 100.0% 100.0% 100.0% 100.0%Cost of products sold 31.3 32.2 31.3 30.5 29.8 Gross profit 68.7 67.8 68.7 69.5 70.2 Selling, marketing & administrative expense 30.6 31.0 32.3 31.5 32.0 Research expense 11.5 11.4 11.6 11.1 11.3 Earnings before provision for taxes on income 21.7 20.5 19.0 27.5 25.4 Provision for taxes on income 2.3 4.9 4.1 5.8 5.6 Net earnings attributable to Johnson & Johnson 19.4 16.1 14.9 21.7 19.8

(1) For Adjusted earnings (before and after tax) and adjusted earnings per share, see Reconciliation of Non-GAAP Measures on Page 19.

5

Johnson & Johnson and Subsidiaries:Consolidated Statements of Cash Flows (Dollars in Millions)

2013 2012 2011Cash flows from operationsNet earnings 13,831$ 10,514 9,672 Adjustments to reconcile net earnings to cash flows: Depreciation and amortization of property and intangibles 4,104 3,666 3,158 Stock Based Compensation 728 662 621

Noncontrolling interest - 339 - Venezuela currency devaluation 108 - - Asset write-downs 739 2,131 160 Net gain on equity investment transactions (417) - -

Deferred tax provision (607) (39) (836) Accounts receivable allowances (131) 92 32 Changes in assets and liabilities, net of effects from acquisitions: (Increase)/Decrease in accounts receivable (632) (9) (915) (Increase)/Decrease in inventories (622) (1) (715) Increase/(Decrease) in accounts payable and accrued liabilities 1,821 2,768 493 (Increase)/Decrease in other current and non-current assets (1,806) (2,172) (1,785) Increase/(Decrease) in other current and non-current liabilities 298 (2,555) 4,413 Net cash flows from operating activities 17,414 15,396 14,298

Cash flows from investing activitiesAdditions to property, plant and equipment (3,595) (2,934) (2,893) Proceeds from the disposal of assets 458 1,509 1,342 Acquisitions, net of cash acquired (835) (4,486) (2,797) Purchases of investments (18,923) (13,434) (29,882) Sales of investments 18,058 14,797 30,396 Other (266) 38 (778) Net cash used by investing activities (5,103) (4,510) (4,612)

Cash flows from financing activitiesDividends to shareholders (7,286) (6,614) (6,156) Repurchase of common stock (3,538) (12,919) (2,525) Proceeds from short-term debt 1,411 3,268 9,729 Retirement of short-term debt (1,397) (6,175) (11,200) Proceeds from long-term debt 3,607 45 4,470 Retirement of long-term debt (1,593) (804) (16) Proceeds from the exercise of stock options/excess tax benefits 2,649 2,720 1,246 Other 56 (83) - Net cash used by financing activities (6,091) (20,562) (4,452)

Effect of exchange rate changes on cash and cash equivalents (204) 45 (47) Increase/(Decrease) in cash and cash equivalents 6,016 (9,631) 5,187 Cash and cash equivalents, beginning of year 14,911 24,542 19,355 Cash and cash equivalents, end of year 20,927$ 14,911 24,542

Supplemental cash flow dataCash paid during the year for: Interest 596$ 616 576 Interest, net of amount capitalized 491$ 501 492 Income taxes 3,155 2,507 2,970

Supplemental schedule of noncash investing and financing activitiesIssuance of common stock associated with the acquisition of Synthes, Inc. -$ 13,335 - Treasury stock issued for employee compensation and stock option plans, net of cash proceeds 743 615 433 Conversion of debt 22 - 1

Acquisition of businessesFair value of assets acquired 1,028$ 19,025 3,025 Fair value of liabilities assumed and noncontrolling interests (193) (1,204) (228) Net fair value of acquisitions 835$ 17,821 2,797 Less: Issuance of common stock associated with the acquisition of Synthes, Inc. - 13,335 -

Net cash paid for acquisitions 835$ 4,486 2,797

6

Johnson & Johnson and Subsidiaries:Segments of Business (Dollars in Millions)

Sales to Customers 2013 (1) 2012 (2) 2011 (3) 2010 (4) 2009 (5)

Consumer United States 5,162$ 5,046 5,151 5,519 6,837 International 9,535 9,401 9,732 9,071 8,966 Total 14,697 14,447 14,883 14,590 15,803 Pharmaceutical United States 13,948 12,421 12,386 12,519 13,041 International 14,177 12,930 11,982 9,877 9,479 Total 28,125 25,351 24,368 22,396 22,520 Medical Devices and Diagnostics United States 12,800 12,363 11,371 11,412 11,011 International 15,690 15,063 14,408 13,189 12,563 Total 28,490 27,426 25,779 24,601 23,574 Worldwide United States 31,910 29,830 28,908 29,450 30,889 International 39,402 37,394 36,122 32,137 31,008 Total 71,312$ 67,224 65,030 61,587 61,897

Pre-Tax ProfitConsumer 1,973$ 1,693 2,096 2,342 2,475 Pharmaceutical 9,178 6,075 6,406 7,086 6,413 Medical Devices and Diagnostics 5,261 7,187 5,263 8,272 7,694 Segments Total 16,412 14,955 13,765 17,700 16,582 Less: Expenses/(Income) not allocated to segments (6) 941 1,180 1,404 753 827 Worldwide Total 15,471$ 13,775 12,361 16,947 15,755

Pre-Tax Profit as % of Segment SalesConsumer 13.4% 11.7% 14.1% 16.1% 15.7%Pharmaceutical 32.6% 24.0% 26.3% 31.6% 28.5%Medical Devices and Diagnostics 18.5% 26.2% 20.4% 33.6% 32.6%Segments Total 23.0% 22.2% 21.2% 28.7% 26.8%Worldwide Total 21.7% 20.5% 19.0% 27.5% 25.4%

Identifiable AssetsConsumer 23,711$ 24,131 24,210 23,753 24,671 Pharmaceutical 23,783 23,219 23,747 19,961 21,460 Medical Devices and Diagnostics 44,585 42,926 23,609 23,277 22,853 Segments Total 92,079 90,276 71,566 66,991 68,984 General corporate (7) 40,604 31,071 42,078 35,917 25,698 Worldwide Total 132,683$ 121,347 113,644 102,908 94,682

(7) General corporate includes cash & marketable securities.

(6) Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes expense of $0.2 billion and $0.5 billion of currency related expense related to the acquisition of Synthes, Inc. in 2012 and 2011, respectively.

(1) 2013 pre-tax profit includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Diagnostics and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $251 million expense for the cost associated with the DePuy ASR TM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively. (2) 2012 pre-tax profit includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.(3) 2011 pre-tax profit includes $3,310 million of net litigation expense comprised of $1,741 million and $1,569 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $656 million of net restructuring expense, comprised of $676 million expense in the Medical Devices and Diagnostics segment and a gain of $20 million in the Pharmaceutical segment. The Medical Devices and Diagnostics segment also includes $521 million expense for the cost associated with the DePuy ASR™ Hip program.(4) 2010 pre-tax profit includes $397 million of net litigation gain comprised of $447 million expense in the Pharmaceutical segment and a gain of $844 million in the Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment also includes $280 million expense for the cost associated with the DePuy ASR™ Hip program.(5) 2009 pre-tax profit includes $1,186 million of restructuring expense, comprised of $369 million, $496 million, and $321 million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments, respectively. Includes $386 million of fourth quarter net litigation gain, comprised of a $92 million expense in the Pharmaceutical segment and a gain of $478 million in the Medical Devices and Diagnostics segment.

7

Johnson & Johnson and Subsidiaries:Segments of Business (Dollars in Millions)

Additions to Property, Plant and Equipment 2013 2012 2011 2010 2009Consumer 533$ 468 670 526 439 Pharmaceutical 856 737 729 508 535 Medical Devices and Diagnostics 1,724 1,230 1,095 1,113 1,114 Segments Total 3,113 2,435 2,494 2,147 2,088 General corporate 482 499 399 237 277 Worldwide Total 3,595$ 2,934 2,893 2,384 2,365

Depreciation & Amortization Consumer 539$ 575 631 532 513 Pharmaceutical 1,075 1,010 958 912 922 Medical Devices and Diagnostics 2,224 1,857 1,331 1,270 1,124 Segments Total 3,838 3,442 2,920 2,714 2,559 General corporate 266 224 238 225 215 Worldwide Total 4,104$ 3,666 3,158 2,939 2,774

Research Expense and DevelopmentConsumer segment 590$ 622 659 609 632 Pharmaceutical segment 5,810 5,362 5,138 4,432 4,591 Med Devices and Diagnostics segments 1,783 1,681 1,751 1,803 1,763 Worldwide total 8,183$ 7,665 7,548 6,844 6,986

Research Expense as a Percent of Segment SalesConsumer segment 4.0% 4.3% 4.4% 4.2% 4.0%Pharmaceutical segment 20.7% 21.2% 21.1% 19.8% 20.4%Med Devices and Diagnostics segments 6.3% 6.1% 6.8% 7.3% 7.5%Worldwide total 11.5% 11.4% 11.6% 11.1% 11.3%

Pharmaceutical Research Expense as a Percent of total J&J WW Sales 8.1% 8.0% 7.9% 7.2% 7.4%

8

Johnson & Johnson and Subsidiaries:Geographical Areas (Dollars in Millions)

Sales to Customers 2013 2012 2011 2010 2009United States 31,910$ 29,830 28,908 29,450 30,889 Europe 18,599 16,945 17,129 15,510 15,934 Western Hemisphere excluding U.S. 7,421 7,207 6,418 5,550 5,156 Asia-Pacific, Africa 13,382 13,242 12,575 11,077 9,918 Total 71,312$ 67,224 65,030 61,587 61,897

Long-Lived AssetsUnited States 35,880$ 35,115 23,529 23,315 22,399 Europe 24,868 25,261 19,056 16,791 17,347 Western Hemisphere excluding U.S. 3,281 3,636 3,517 3,653 3,540 Asia-Pacific, Africa 2,434 2,362 2,163 2,089 1,868 Segments total 66,463 66,374 48,265 45,848 45,154 General corporate 992 899 750 715 790 Other non long-lived assets 65,228 54,074 64,629 56,345 48,738 Worldwide total 132,683$ 121,347 113,644 102,908 94,682

9

Johnson & Johnson and Subsidiaries:Sales Growth Rates

2013 2012 2011 2010 2009

United States 7.0% 3.2% -1.8% -4.7% -4.4%Operations 7.0% 3.2% -1.8% -4.7% -4.4%

International 5.4% 3.5% 12.4% 3.6% -1.4%Operations 8.2% 8.4% 7.0% 1.9% 3.9%Currency -2.8% -4.9% 5.4% 1.7% -5.3%

Worldwide 6.1% 3.4% 5.6% -0.5% -2.9%Operations 7.7% 6.1% 2.8% -1.3% -0.3%Currency -1.6% -2.7% 2.8% 0.8% -2.6%

Compound Growth RatesUnited States International Worldwide

2008-2013 (5 Yr.) -0.2% 4.6% 2.3%2003-2013 (10 Yr.) 2.4% 9.0% 5.5%

10

Johnson & Johnson and Subsidiaries:Quarterly Sales by Segment (Dollars in Millions)

Year U.S. Int'l WW U.S. Int'l WW

1Q 2009 1,726 1,985 3,711 3,674 2,106 5,780 2Q 2009 1,708 2,146 3,854 3,172 2,326 5,498 3Q 2009 1,691 2,298 3,989 2,857 2,392 5,249 4Q 2009 1,712 2,537 4,249 3,338 2,655 5,993

2009 6,837 8,966 15,803 13,041 9,479 22,520

1Q 2010 1,560 2,206 3,766 3,206 2,432 5,638 2Q 2010 1,463 2,184 3,647 3,110 2,443 5,553 3Q 2010 1,277 2,290 3,567 3,054 2,441 5,495 4Q 2010 1,219 2,391 3,610 3,149 2,561 5,710

2010 5,519 9,071 14,590 12,519 9,877 22,396

1Q 2011 1,345 2,337 3,682 3,391 2,668 6,059 2Q 2011 1,339 2,454 3,793 3,239 2,994 6,233 3Q 2011 1,219 2,521 3,740 2,869 3,113 5,982 4Q 2011 1,248 2,420 3,668 2,887 3,207 6,094

2011 5,151 9,732 14,883 12,386 11,982 24,368

1Q 2012 1,316 2,279 3,595 3,026 3,107 6,133 2Q 2012 1,313 2,306 3,619 3,094 3,197 6,291 3Q 2012 1,214 2,367 3,581 3,288 3,114 6,402 4Q 2012 1,203 2,449 3,652 3,013 3,512 6,525

2012 5,046 9,401 14,447 12,421 12,930 25,351

1Q 2013 1,348 2,327 3,675 3,471 3,297 6,768 2Q 2013 1,326 2,332 3,658 3,377 3,648 7,025 3Q 2013 1,225 2,386 3,611 3,549 3,487 7,036 4Q 2013 1,263 2,490 3,753 3,551 3,745 7,296

2013 5,162 9,535 14,697 13,948 14,177 28,125

Consumer Pharmaceutical

11

Johnson & Johnson and Subsidiaries:Quarterly Sales by Segment (Dollars in Millions)

Year U.S. Int'l WW U.S. Int'l WW

1Q 2009 2,652 2,883 5,535 8,052 6,974 15,026 2Q 2009 2,776 3,111 5,887 7,656 7,583 15,239 3Q 2009 2,766 3,077 5,843 7,314 7,767 15,081 4Q 2009 2,817 3,492 6,309 7,867 8,684 16,551

2009 11,011 12,563 23,574 30,889 31,008 61,897

1Q 2010 2,886 3,341 6,227 7,652 7,979 15,631 2Q 2010 2,865 3,265 6,130 7,438 7,892 15,330 3Q 2010 2,800 3,120 5,920 7,131 7,851 14,982 4Q 2010 2,861 3,463 6,324 7,229 8,415 15,644

2010 11,412 13,189 24,601 29,450 32,137 61,587

1Q 2011 2,872 3,560 6,432 7,608 8,565 16,173 2Q 2011 2,869 3,702 6,571 7,447 9,150 16,597 3Q 2011 2,780 3,503 6,283 6,868 9,137 16,005 4Q 2011 2,850 3,643 6,493 6,985 9,270 16,255

2011 11,371 14,408 25,779 28,908 36,122 65,030

1Q 2012 2,877 3,534 6,411 7,219 8,920 16,139 2Q 2012 2,953 3,612 6,565 7,360 9,115 16,475 3Q 2012 3,289 3,780 7,069 7,791 9,261 17,052 4Q 2012 3,244 4,137 7,381 7,460 10,098 17,558

2012 12,363 15,063 27,426 29,830 37,394 67,224

1Q 2013 3,206 3,856 7,062 8,025 9,480 17,505 2Q 2013 3,243 3,951 7,194 7,946 9,931 17,877 3Q 2013 3,151 3,777 6,928 7,925 9,650 17,575 4Q 2013 3,200 4,106 7,306 8,014 10,341 18,355

2013 12,800 15,690 28,490 31,910 39,402 71,312

Medical Devices and Diagnostics Total

12

Johnson & Johnson and Subsidiaries:Quarterly Statement of Earnings (1) (Dollars in Millions except per share figures)

Year SalesCost of

Products Sold SM&A R&D

In-process Research and Development

Net Interest Exp. (Inc.)

Other Exp. (Inc.)

1Q 2013 17,505$ 5,554$ 5,223$ 1,784$ 64$ 104$ 515$ 2Q 2013 17,877 5,489 5,376 1,946 - 101 172 3Q 2013 17,575 5,344 5,314 2,042 178 87 943 4Q 2013 18,355 5,955 5,917 2,411 338 116 868

2013 71,312$ 22,342$ 21,830$ 8,183$ 580$ 408$ 2,498$

Year SalesCost of

Products Sold Gross Margin SM&A R&D

In-process Research and Development

Net Interest Exp. (Inc.)

1Q 2013 100.0% 31.7% 68.3% 29.8% 10.2% 0.4% 0.6%2Q 2013 100.0% 30.7% 69.3% 30.1% 10.9% 0.0% 0.6%3Q 2013 100.0% 30.4% 69.6% 30.2% 11.6% 1.0% 0.5%4Q 2013 100.0% 32.5% 67.5% 32.2% 13.1% 1.9% 0.6%

2013 100.0% 31.3% 68.7% 30.6% 11.5% 0.8% 0.6%

(1) Net Earnings are GAAP and therefore, do not exclude special items. Refer to Page 19, Reconciliation of Non-GAAP Measures, for an analysis of 2009-2013 Full Year Adjusted Earnings

Quarterly Statement of Earnings - as a % of Sales

13

Johnson & Johnson and Subsidiaries:Quarterly Statement of Earnings (Continued) (1) (Dollars in Millions except per share figures)

YearTotal Cost &

ExpenseEarnings

Before Taxes

Provision for/(Benefit from) Taxes on Income Net Earnings

Basic Earnings per

Share

Basic Average Shares

Diluted Earnings per

Share

Diluted Average Shares

1Q 2013 13,244$ 4,261$ 764$ 3,497$ 1.25$ 2,790.2 1.22$ 2,858.8 2Q 2013 13,084 4,793 960 3,833 1.36 2,809.7 1.33 2,893.0 3Q 2013 13,908 3,667 685 2,982 1.06 2,818.4 1.04 2,881.2 4Q 2013 15,605 2,750 (769) 3,519 1.25 2,821.1 1.23 2,872.0

2013 55,841$ 15,471$ 1,640$ 13,831$ 4.92$ 2,809.2 4.81$ 2,877.0

YearOther Exp.

(Inc.)Total Cost &

ExpenseEarnings

Before Taxes

Provision for/(Benefit from) Taxes on Income

Income Taxes (Eff. Rate) Net Earnings

1Q 2013 3.0% 75.7% 24.3% 4.3% 17.9% 20.0%2Q 2013 0.9% 73.2% 26.8% 5.4% 20.0% 21.4%3Q 2013 5.4% 79.1% 20.9% 3.9% 18.7% 17.0%4Q 2013 4.7% 85.0% 15.0% -4.2% -28.0% 19.2%

2013 3.5% 78.3% 21.7% 2.3% 10.6% 19.4%

(1) Net Earnings are GAAP and therefore, do not exclude special items. Refer to Page 19, Reconciliation of Non-GAAP Measures, for an analysis of 2009-2013 Full Year Adjusted Earnings

Quarterly Statement of Earnings - as a % of Sales

14

Johnson & Johnson and Subsidiaries:Sales and Net Earnings (2) 1887 - 2013 (1) (Dollars in Millions)

Year Net Trade

Sales Net

Earnings Year Net Trade

Sales Net

Earnings Year Net Trade Sales (1) Net Earnings

1931 17.4 1.3 1976 2,522.5 205.4 1887 0.1$ 1932 15.2 1.1 1977 2,914.1 247.3 1888 0.2 1933 17.1 0.9 1978 3,497.3 299.1 1889 0.3 1934 20.7 1.0 1979 4,211.6 352.1 1890 0.4 1935 24.7 1.3 1980 4,837.4 400.7 1891 0.4 1936 28.9 2.1 1981 5,399.0 467.6 1892 0.5 1937 32.3 1.7 1982 5,760.9 473.0 1893 0.5 1938 33.4 2.7 1983 5,972.9 489.0 1894 0.6 1939 35.1 3.7 1984 6,124.5 514.5 1895 0.6 1940 39.1 2.4 1985 6,421.3 613.7 1896 0.7 1941 56.6 3.2 1986 7,003.0 330.0 1897 0.7 0.19$ 1942 78.2 2.8 1987 8,011.5 833.0 1898 0.9 0.13 1943 93.1 3.1 1988 8,999.5 974.0 1899 1.1 0.20 1944 93.6 3.1 1989 9,829.0 1,082.0 1900 1.3 0.23 1945 96.0 3.1 1990 11,365.0 1,080.0 1901 1.4 0.23 1946 112.6 8.3 1991 12,210.0 1,270.0 1902 1.6 0.27 1947 152.3 9.9 1992 13,600.0 977.0 1903 1.8 0.28 1948 165.6 12.1 1993 13,877.0 1,786.0 1904 2.0 0.36 1949 168.3 10.0 1994 15,454.0 1,961.0 1905 2.4 0.33 1950 195.5 15.7 1995 18,537.0 2,416.0 1906 2.7 0.53 1951 227.6 12.3 1996 21,387.0 2,942.0 1907 3.0 0.77 1952 232.2 8.8 1997 22,522.0 3,070.0 1908 2.9 0.54 1953 236.1 11.2 1998 23,811.0 3,024.0 1909 3.2 0.63 1954 243.5 12.2 1999 27,357.0 4,133.0 1910 3.9 0.67 1955 267.5 14.0 2000 29,172.0 4,764.0 1911 4.4 0.54 1956 293.6 15.6 2001 32,317.0 5,405.0 1912 4.6 1.05 1957 315.6 16.9 2002 36,298.0 6,277.0 1913 4.8 0.75 1958 321.2 15.1 2003 41,862.0 6,848.0 1914 5.0 0.63 1959 368.4 19.7 2004 47,348.0 8,180.0 1915 5.1 0.74 1960 384.4 20.2 2005 50,514.0 10,060.0 1916 6.2 1.11 1961 414.5 17.7 2006 53,324.0 11,053.0 1917 9.6 1.22 1962 447.6 19.9 2007 61,095.0 10,576.0 1918 13.7 1.37 1963 462.4 21.5 2008 63,747.0 12,949.0 1919 11.2 0.83 1964 503.3 26.8 2009 61,897.0 12,266.0 1920 15.2 0.50 1965 576.0 34.4 2010 61,587.0 13,334.0 1921 12.5 1.30 1966 660.6 40.1 2011 65,030.0 9,672.0 1922 13.7 1.90 1967 712.3 45.9 2012 67,224.0 10,853.0 1923 15.5 1.80 1968 801.3 57.6 2013 71,312.0$ 13,831.0$ 1924 16.0 1.80 1969 901.9 69.4 1925 16.2 2.10 1970 1,002.0 83.7 1926 16.5 2.00 1971 1,140.5 101.8 1927 16.8 1.50 1972 1,317.7 120.7 1928 18.4 0.80 1973 1,611.8 148.4 1929 19.9 1.60 1974 1,937.2 161.6 1930 18.7 1.20 1975 2,224.7 183.8

(1) Sales restated for EITF change for 1991-2001 only. Net Earnings restated for FAS 123R Share Based Payment for 1996-2005.(2) Net Earnings attributable to Johnson & Johnson.Note: 1887-1989 information not restated and may include estimates.

Refer to Page 19, Reconciliation of Non-GAAP Measures, for an analysis of 2009-2013 Adjusted Earnings. Note: Net Earnings are reported according to GAAP and therefore do not exclude special items.

15

Johnson & Johnson and Subsidiaries:Stock Split and Share Repurchase Information (Dollars in Millions)

Stock Splits

Pay Out Date ActionMay 5, 1947 100% Stock DividendNovember 15, 1948 5% Stock DividendNovember 15, 1949 5% Stock DividendMarch 20, 1951 5% Stock DividendJanuary 9, 1959 2 1/2 for 1 Split June 19, 1967 200% Stock DividendMay 15, 1970 3 for 1 SplitMay 18, 1981 3 for 1 SplitMay 10, 1989 2 for 1 SplitJune 9, 1992 2 for 1 SplitJune 11, 1996 2 for 1 SplitJune 12, 2001 2 for 1 Split

Share Repurchase Program*Total Shares Total Value Avg. Price

Year (Millions) (Dollars in Millions) Per Share

1984 160.0 $329 $2.05501986 160.0 670 4.18651988 97.8 500 5.12301992 42.4 500 11.79751993 49.6 500 10.06252002 83.6 5,000 59.79942006 81.8 5,000 61.12472007 55.8 3,600 64.58702008 69.1 4,500 65.12302009 15.5 800 51.61292010 17.9 $1,100 $61.4525

* Total value may be rounded. In addition, the Company repurchases shares annually for use in employee stock option and employee incentive plans. In 1990, the Company repurchased 12.8 million shares for a total value of $100 million in connection with the establishment of an ESOP. All shares and average price per share have been adjusted for stock split.

16

Johnson & Johnson and Subsidiaries:Common Stock Information 1944-2013 (Price per share/Shares in Millions)

YEARLY YEARLY YEARLY YEAR-END YEARLY NET SHARES P/EYEAR HIGH LOW AVERAGE PRICE DIVIDEND OUTSTANDING* RATIO

9/25/44 (open) $ 0.02 2,213.61944 $ 0.02 $ 0.01 $ 0.02 0.01 $ 0.00008 2,213.6 101945 0.03 0.02 0.02 0.02 0.00012 2,242.7 191946 0.03 0.02 0.02 0.03 0.00012 2,264.0 71947 0.03 0.02 0.03 0.02 0.00020 2,276.0 61948 0.03 0.03 0.03 0.03 0.00067 2,243.1 61949 0.05 0.03 0.03 0.05 0.00115 2,247.9 121950 0.07 0.04 0.05 0.07 0.00176 2,260.2 121951 0.08 0.06 0.07 0.06 0.00102 2,264.1 181952 0.07 0.05 0.06 0.06 0.00093 2,259.8 151953 0.06 0.05 0.06 0.06 0.00152 2,268.4 151954 0.07 0.06 0.06 0.07 0.00152 2,274.9 171955 0.08 0.06 0.07 0.07 0.00152 2,270.4 151956 0.08 0.06 0.07 0.07 0.00152 2,276.6 121957 0.09 0.07 0.08 0.08 0.00167 2,288.0 141958 0.14 0.08 0.11 0.12 0.00157 2,290.3 221959 0.17 0.11 0.16 0.14 0.00185 2,558.8 231960 0.18 0.13 0.16 0.17 0.00231 2,563.5 281961 0.26 0.17 0.22 0.24 0.00231 2,586.3 311962 0.26 0.14 0.22 0.17 0.00231 2,584.8 241963 0.29 0.17 0.24 0.24 0.00255 2,591.9 291964 0.28 0.22 0.25 0.26 0.00278 2,574.6 271965 0.40 0.26 0.35 0.40 0.00336 2,603.0 321966 0.47 0.32 0.41 0.40 0.00382 2,588.2 281967 0.67 0.38 0.50 0.64 0.00428 2,606.1 331968 0.75 0.52 0.63 0.74 0.00451 2,619.4 341969 1.26 0.70 0.99 1.25 0.00590 2,656.4 411970 1.25 0.89 1.06 1.19 0.00708 2,676.3 431971 2.08 1.18 1.74 2.05 0.00896 2,690.8 541972 2.77 1.96 2.50 2.72 0.00932 2,708.1 591973 2.76 2.11 2.47 2.35 0.01094 2,761.1 411974 2.49 1.52 1.97 1.69 0.01510 2,773.6 281975 2.08 1.51 1.85 1.87 0.01771 2,785.7 301976 2.01 1.49 1.84 1.63 0.02188 2,796.1 221977 1.63 1.30 1.46 1.60 0.02917 2,808.3 161978 1.86 1.37 1.61 1.54 0.03542 2,872.9 141979 1.68 1.35 1.52 1.65 0.04167 2,938.2 121980 2.11 1.38 1.67 2.08 0.04646 2,966.6 151981 2.46 1.77 2.06 2.32 0.05313 2,993.0 151982 3.20 2.03 2.55 3.10 0.06625 3,026.0 161983 3.22 2.44 2.86 2.55 0.06750 3,061.3 141984 2.68 1.75 2.16 2.26 0.07375 2,925.5 141985 3.45 2.20 2.78 3.29 0.08000 2,925.6 151986 4.64 2.86 3.97 4.10 0.08625 2,765.6 431987 6.59 3.44 5.28 4.68 0.10063 2,753.5 171988 5.51 4.35 5.06 5.32 0.12000 2,664.6 161989 7.44 5.19 6.25 7.42 0.14000 2,679.4 191990 9.27 6.39 7.85 8.97 0.16375 2,700.4 211991 14.53 8.17 11.19 14.31 0.19250 2,713.4 301992 14.67 10.75 12.34 12.63 0.22250 2,674.2 231993 12.60 8.91 10.50 11.22 0.25250 2,627.8 171994 14.13 9.00 11.54 13.69 0.28250 2,645.0 191995 23.10 13.41 17.19 21.38 0.32000 2,665.6 25

17

Johnson & Johnson and Subsidiaries:Common Stock Information 1944-2013 (Price per share/Shares in Millions)

YEARLY YEARLY YEARLY YEAR-END YEARLY NET SHARES P/EYEAR HIGH LOW AVERAGE PRICE DIVIDEND OUTSTANDING* RATIO

1996 27.00 20.78 24.29 24.88 0.36750 2,753.4 251997 33.66 24.32 29.82 32.97 0.42500 2,971.6 321998 44.88 31.69 37.46 41.94 0.48500 2,975.3 411999 53.44 38.50 46.99 46.63 0.54500 2,979.6 342000 52.97 33.07 44.64 52.53 0.62000 3,014.6 332001 60.97 40.25 51.88 59.86 0.70000 3,047.2 342002 65.89 41.40 57.67 53.11 0.79500 2,968.3 252003 59.08 48.05 52.62 50.62 0.92500 2,967.9 222004 64.25 49.25 55.84 63.42 1.09500 2,971.0 232005 64.60 59.76 64.70 60.10 1.27500 2,971.0 182006 69.41 56.70 62.21 66.02 1.45500 2,893.2 182007 68.75 59.72 63.98 67.38 1.62000 2,840.2 182008 72.76 52.06 64.91 58.56 1.79500 2,769.2 132009 65.41 46.25 56.88 64.41 1.93000 2,754.3 152010 66.20 56.86 62.16 61.85 2.11000 2,738.1 132011 68.05 57.50 63.56 65.58 2.25000 2,724.4 192012 72.74 61.71 66.95 69.48 2.40000 2,778.5 182013 95.99 69.18 85.65 92.35 2.59000 2,820.6 19

* Net shares outstanding = shares issued less treasury stock at Johnson & Johnson year-end close.Note: All data adjusted for prior stock splits; shares outstanding are actual J&J year-end close; year -end share price per Yahoo Finance at J&J year-end close; P/E ratio based on fiscal year-end closing price.

18

Johnson & Johnson and Subsidiaries:Reconciliation of Non-GAAP Measures (Dollars in Millions except per share amounts)

2013 2012 2011 2010 2009Earnings before provision for taxes on income- as reported 15,471$ 13,775 12,361 16,947 15,755 Net litigation loss (gain) 2,282 1,229 3,310 (397) (386) Intangible asset write-downs - 939 - - - Restructuring expense - - 656 - 1,186 DePuy ASRTM Hip program 251 110 521 280 - Synthes integration/transaction costs and currency related 683 1,028 491 - - In-process research & development (IPR&D)(1) 580 1,163 14 - - Other (98) (30) - - - Earnings before provision for taxes on income- as adjusted 19,169$ 18,214 17,353 16,830 16,555

Net Earnings(2) - as reported 13,831$ 10,853 9,672 13,334 12,266 Net litigation loss (gain) 1,646 1,052 2,745 (294) (212) Intangible asset write-downs - 717 - - - Restructuring expense - - 536 - 852 DePuy ASRTM Hip program 240 97 426 239 - Synthes integration/transaction costs and currency related 483 899 477 - - In-process research & development (IPR&D)(1) 462 743 (3) 11 - - Scios Tax Benefit (707) - - - - Other (79) (16) - - - Net Earnings(2) - as adjusted 15,876$ 14,345 13,867 13,279 12,906

Diluted net earnings per share(2) - as reported 4.81$ 3.86 3.49 4.78 4.40 Net litigation loss (gain) 0.57 0.37 0.99 (0.11) (0.08) Intangible asset write-downs - 0.26 - - - Restructuring expense - - 0.19 - 0.31 DePuy ASRTM Hip program 0.08 0.03 0.16 0.09 - Synthes integration/transaction costs and currency related 0.17 0.32 0.17 - - In-process research & development (IPR&D)(1) 0.16 0.27 - - - Scios Tax Benefit (0.25) - - - - Other (0.02) (0.01) - - - Diluted net earnings per share(2) - as adjusted 5.52$ 5.10 5.00 4.76 4.63

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

(1) In 2009, in accordance with U.S. GAAP for business combinations, purchased in-process research and development is no longer expensed, but capitalized and tested for impairment.

(3) Amount includes third quarter in-process research and development charge of $679M related to bapineuzumab IV offset by $339M reported as net loss attributable to noncontrolling interest

(2) Attributable to Johnson & Johnson

19

Principal Office One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (732) 524-0400 Common Stock Listed on New York Stock Exchange Stock Symbol: JNJ Annual Meeting The Annual Meeting of Shareholders will take place on Thursday, April 24, 2014, at the Hyatt Regency Hotel, Two Albany Street, New Brunswick, New Jersey. The meeting will convene at 10 a.m. All shareholders as of the record date of February 25, 2014 are cordially invited to attend. A formal Notice of Annual Meeting, Proxy Statement and Proxy have been sent to shareholders. Transfer Agent and Registrar Questions regarding stock holdings, certificate replacement/transfer, dividends and address changes should be directed to: Computershare Trust Company, N.A. 250 Royall St. Canton, MA 02021 (800) 328-9033 or (781) 575-2718 (outside the U.S.) www.computershare.com

Dividend Reinvestment Plan The Plan allows for full or partial dividend reinvestment and additional monthly cash investments up to $50,000 per year in Johnson & Johnson Common Stock without brokerage commissions or service charges on stock purchases. If you are interested in participating in the Plan and need an authorization form and/or more information, please call Computershare Trust Company, N.A. at (800) 328-9033 or (781) 575-2718 (outside the U.S.). Shareholder Relations Contact Douglas K. Chia Corporate Secretary (732) 524-2455

Investor Relations Department One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 1-800-950-5089 Fax: (732) 524-3867

Louise Mehrotra Vice President, Investor Relations (732) 524-6492

Stan Panasewicz Senior Director, Investor Relations (732) 524-2524 Lesley Fishman Senior Director, Investor Relations (732) 524-3922

Sue Hohenleitner Senior Director, Investor Relations (732) 524-3709

Lisa Romanko Senior Director, Investor Relations (732) 524-2034

Renee McKenna Senior Analyst (732) 524-6492 Reports Available Copies of the Company's 2013 Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to the Securities and Exchange Commission, Proxy Statement and the Annual Report are available online at www.jnj.com or to shareholders without charge upon written request to the Secretary at the Company's principal address or by calling (800) 328-9033 or (781) 575-2718 (outside the U.S.)

Press Releases Press releases, including earnings reports, are available via web access http://www.jnj.com

Internet Access Visit the Johnson & Johnson Home Page on the Internet: http://www.jnj.com

© Johnson & Johnson 2013 Trademarks and service marks of Johnson & Johnson and its affiliated companies are designated by all capital letters in this publication

Corporate and Shareholder/Investor Information

20

2013

Description • Through its family of companies, the world’s most comprehensive and

broadly based manufacturer of health care products • Serves the Consumer, Pharmaceutical and Medical Devices and

Diagnostics markets by developing broadly accessible, high quality, innovative products and services that advance the health and well-being of people

Consistent Performance • 30 consecutive years of earnings increases adjusted for special items • 51 consecutive years of dividends increases

One Year2 Five Years2 Ten Years2 Sales 6.1% 2.3% 5.5% Diluted Adjusted Earnings per Share 1

8.2% 3.9% 8.1%

Dividend Growth 7.9% 7.6% 10.8% Total Return to Shareholders 34.6% 12.6% 8.9% 1 Non-GAAP, excludes special items. Reconciliation available in corresponding Annual Reports. 2 Compounded Annual Growth Rates Broadly Based/Exceptional Financial Strength • Over 275 operating companies in 60 countries selling products

throughout the world (approximately 55% of sales outside of U.S.) • Sales split among Consumer, Pharmaceutical and Medical Devices and

Diagnostics business segments • More than 100 drugs marketed; 41 drugs over $50 million; 32 drugs over

$100 million; 8 drugs over $1 billion • One of four U.S. industrial companies that still commands a Triple A

credit rating by both Standard & Poor’s and Moody’s credit rating agencies

• Generated annual free cash flow1 in 2013 of $13.8 billion. 1Non-GAAP financial measure; defined as operating cash flow less capital spending

(1) Net Earnings attributable to Johnson & Johnson

Worldwide Market Leadership • Largest Medical Device company • 7th largest Pharmaceutical company

globally • 6th largest Biotech company globally • 6th largest Consumer Health Care

company globally • Leadership Positions in Major Markets:

• Antithrombotic agents • Antipsychotics (Injectables) • Anti - TNF • Baby Care • Biosurgicals • Blood Glucose Monitoring • Breast Aesthetics • Disposable Contact Lenses • Electrophysiology diagnostics

& catheters • Hormone antagonists • Infection Prevention • Lo-Cal Sweeteners • Minimally Invasive Surgery • Oral Rinses • Orthopaedics • OTC Analgesics • Sanitary Protection • Sutures • Systemic Antipsoriasis

products • Wound Care

• Approximately 70% of sales are derived from products/businesses that have a #1 or #2 global market share position

2013 Worldwide Sales $71.3 Billion

2013 Investor Fact Sheet

Approximately ##%

Please visit our Home Page on the Internet at http://www.jnj.com for requests for Company Reports, including the 2013 Annual Report and SEC filings. Questions regarding stock holdings and the Dividend Reinvestment Plan, should be directed to: Computershare Trust Company,N.A. Phone (800) 328-9033

2003

$6,848

2008

Net Earnings(1) (as reported) $U.S. Millions $12,949

$13,831

Approximately 25%

New Products Introduced in Past 5 Years

21

Strong Commitment to New Product Development • $8.2 billion in Research &

Development expense in 2013 • Numerous external alliances and

collaborations entered into annually

• Approximately 25% of products sold in 2013 introduced in last 5 years

Management Based on a Core Set of Strategic Principles • Creating Value through Innovation

o Robust pipeline of new and innovative products

• Global Reach/Local Focus o Broad geographic reach

provides ability to rapidly introduce new products in markets around the world

• Excellence in Execution o Maintaining high quality

products and standards • Leading with a Purpose

o Focus on products which increase access, reduce cost and improve the quality of health care

Investor Information NYSE Symbol: JNJ For additional information, contact: Investor Relations Department One Johnson & Johnson Plaza New Brunswick, NJ 08933 Voice: (800) 950-5089 Fax: (732) 524-3867 Press releases, including earnings reports, are available via web access: http://www.jnj.com

$18.6

$7.4$13.4

$31.9

80105130155180205230

2003 2005 2007 2009 2011 2013

DO

LLA

RS

Johnson & JohnsonS&P 500S&P PharmS&P H/C Equip

2013 Sales by Geographic Area $U.S. Billions

Shareholder Return Comparison $100 Dollars invested December 31, 2003

This chart provides a comparison of cumulative total shareholder return for an investment in Johnson & Johnson Common Stock as of December 31, 2013 to a similar investment in the identified indices. Assuming dividends were reinvested, a $100.00 investment in Johnson & Johnson would have grown to $235.59 as of December 31, 2013. This compares to a value of $204.26 for the S&P 500 Stock Index, $193.25 for the S&P Pharmaceutical Index and $166.10 for the S&P Healthcare Equipment Index. Source: Bloomberg

Europe

U.S.

Western Hemisphere

Asia-Pacific Africa

45%

26%

10%

19%

$28.5

$28.1

$14.7

2013 Sales by Segment $U.S. Billions

21% 40%

39%

MD&D

Pharmaceutical

Consumer

InternationalU.S.

Net Trade Sales $U.S. Billions

2003 2008 2013

© Johnson & Johnson 2013

$71.3

$63.7

$41.9

22